drugset

Drugs / buformin

Follow last change Dec 2021 re-read 2 minutes ago

buformin

also known as Buformin hydrochloride · Buformina · Buformine · Cinobufacini Tablets

Developed for: diffuse large B-cell lymphoma
Investigated by: Xinjiang Medical University

Trials 1 · a red edge is where a trial was stopped

today NCT02871869 · Ph 2/3

2017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT02871869	Sep 2016 → Sep 2018	diffuse large B-cell lymphoma	Xinjiang Medical University	Unknown	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01584232 Background	Apr 2012 → Jul 2013	type 2 diabetes mellitus	Eli Lilly and Company	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	buformin	“OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗
Known as	Buformin hydrochloride	ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗
Known as	Buformina	ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗
Known as	Buformine	ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗
Known as	Cinobufacini Tablets	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871869 ↗
Modality	Small molecule	— CHEMBL39736 ↗
Route	Oral	“0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities” NCT02871869 ↗